Aldeyra Therapeutics
ALDX
22 hedge funds and large institutions have $47.9M invested in Aldeyra Therapeutics in 2016 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 7 increasing their positions, 3 reducing their positions, and 4 closing their positions.
133% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 3
32% more capital invested
Capital invested by funds: $36.2M → $47.9M (+$11.7M)
12% less funds holding
Funds holding: 25 → 22 (-3)
75% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 4
Top Buyers
| 1 |
PVI
Pura Vida Investments
New York
|
+$223K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$159K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$47.4K |
| 4 |
JP Morgan Chase
New York
|
+$7.33K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$4.56K |
Top Sellers
| 1 |
DM
Deerfield Management
New York
|
-$1.52M |
| 2 |
Millennium Management
New York
|
-$186K |
| 3 |
CL
Croft-Leominster
Baltimore,
Maryland
|
-$96K |
| 4 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
-$14K |
| 5 |
Walleye Trading
New York
|
-$8K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
26
Walleye Trading
New York
| – | -$8K | -1,400 | Closed |
|
ALDX Hedge Fund Activity: Q3 2016 in Review
22 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Aldeyra Therapeutics (ALDX) for Q3 2016, worth a combined $47.9M — up 32% from $36.2M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of ALDX and 1 opened new positions — a net loss of 3 holders — while 3 trimmed existing stakes and 7 added.
The largest buyer was Pura Vida Investments, adding an estimated $223K. The largest seller was Deerfield Management, exiting entirely with an estimated $1.52M sold.
- 22 institutional investors held Aldeyra Therapeutics (ALDX) as of Q3 2016, down from 25 in Q2 2016.
- Funds reported $47.9M of Aldeyra Therapeutics stock for Q3 2016, up 32% quarter-over-quarter.
- 1 fund opened new Aldeyra Therapeutics positions in Q3 2016 and 4 closed out, a net change of -3 holders.
- The largest Aldeyra Therapeutics buyer in Q3 2016 was Pura Vida Investments, an estimated $223K added.
- The largest Aldeyra Therapeutics seller in Q3 2016 was Deerfield Management, an estimated $1.52M sold.
Based on aggregated 13F filings for Q3 2016.